Yamasaki H
Programme of Multistage Carcinogenesis, International Agency for Research on Cancer, Lyon, France.
Cancer Metastasis Rev. 1988 Apr;7(1):5-18. doi: 10.1007/BF00048275.
In undertaking a quantitative estimation of carcinogenesis risk, it is essential to keep in mind that carcinogenesis is a multistage process, and that each stage can be affected by different classes of risk factors. Furthermore, different mechanisms are involved in the various stages of carcinogenesis. Thus, a dose-response analysis of one given factor cannot provide an accurate estimation of carcinogenic risk. Carcinogenic risk estimation is usually undertaken for a specific chemical or group of chemicals; however, the concept of multistage carcinogenesis is based on biological processes and not on the mechanisms of action of the agents involved. It is therefore important to consider three related, but different, factors involved in carcinogenesis: stage, agent, and activity of agent. This is especially important in developing a short-term test for stage-related risk factors, such as tumor-promoting agents. For this reason, carcinogens should not be classified according to only one chemical activity. This article briefly reviews the cellular and molecular mechanisms involved in multistage carcinogenesis, and discusses their implications for risk estimation. Special consideration is given to the effect of treatment frequency on the response of tumor-promoting agents, as seen in long-term tests in experimental animals. It is proposed that exposure frequency be taken into account together with exposure dose.
在对致癌风险进行定量评估时,必须牢记致癌作用是一个多阶段过程,且每个阶段都可能受到不同类别的风险因素影响。此外,致癌作用的各个阶段涉及不同的机制。因此,对某一特定因素进行剂量反应分析无法准确评估致癌风险。致癌风险评估通常针对特定的化学物质或一组化学物质进行;然而,多阶段致癌作用的概念基于生物学过程,而非所涉物质的作用机制。因此,考虑致癌作用中涉及的三个相关但不同的因素很重要:阶段、物质和物质的活性。这在开发针对与阶段相关的风险因素(如促癌剂)的短期试验时尤为重要。出于这个原因,致癌物不应仅根据一种化学活性进行分类。本文简要回顾了多阶段致癌作用所涉及的细胞和分子机制,并讨论了它们对风险评估的影响。特别考虑了治疗频率对促癌剂反应的影响,这在实验动物的长期试验中可见。建议将暴露频率与暴露剂量一并考虑。